<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03242031</url>
  </required_header>
  <id_info>
    <org_study_id>CREUZOT PRME 2015</org_study_id>
    <nct_id>NCT03242031</nct_id>
  </id_info>
  <brief_title>Medico-economic Comparison Between Treatment With Panretinal Photocoagulation by Laser in 1 Session Versus 4 Sessions in Diabetic Retinopathy</brief_title>
  <acronym>LIGHT</acronym>
  <official_title>Medico-economic Evaluation of Treatment With Panretinal Photocoagulation in One Session Using Multispot Laser Versus Four Sessions Using Single-spot Laser in Patients With Severe Non-proliferative and Early Proliferative Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Despite the fact that the efficacy of a single session of multispot laser has been&#xD;
      demonstrated in the treatment of patients with diabetic retinopathy as compared with four&#xD;
      sessions of single-spot laser, the management of panretinal photocoagulation in the different&#xD;
      healthcare establishments in France has remained unchanged notably because there is no&#xD;
      specific reimbursement for this new treatment protocol.&#xD;
&#xD;
      Although the benefits of reducing the number of sessions and thus the costs associated with&#xD;
      the treatment for the patient and the payer seem to be obvious, the medico-economic impact of&#xD;
      modifying the treatment strategy thanks to the technological changes must be evaluated to&#xD;
      provide deciders with additional information.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 21, 2017</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cost of treatment</measure>
    <time_frame>9 months after the start of treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>1 session</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>4 sessions</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>monospot panretinal photocoagulation</intervention_name>
    <description>panretinal photocoagulation with monospot laser</description>
    <arm_group_label>4 sessions</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>multispot panretinal photocoagulation</intervention_name>
    <description>panretinal photocoagulation with multispot laser</description>
    <arm_group_label>1 session</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Persons who have provided written informed consent&#xD;
&#xD;
          -  Patients with type 1 or 2 diabetes according to World Health Organisation diagnostic&#xD;
             criteria.&#xD;
&#xD;
          -  Patients with severe non proliferative or early proliferative diabetic retinopathy&#xD;
&#xD;
          -  Visual acuity of the treated eye &gt;= 20/32 snellen (≥ 0.63 Monoyer units or ≥ 70&#xD;
             letters Early treatment Diabetic Retinopathy Study)&#xD;
&#xD;
          -  Visual acuity of the contralateral eye &gt;= 20/200 snellen (≥ 0.10 Monoyer units or ≥ 35&#xD;
             letters Early treatment Diabetic Retinopathy Study)&#xD;
&#xD;
          -  Patients with a central macular thickness of 350 μm or less on Spectral Domain -&#xD;
             Optical Coherence Tomography&#xD;
&#xD;
          -  Patients with national health insurance cover&#xD;
&#xD;
          -  Patients over 18 years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled diabetes in the previous 6 months with intensive insulin therapy&#xD;
             (glycated haemoglobin &gt; 11).&#xD;
&#xD;
          -  Uncontrolled hypertension.&#xD;
&#xD;
          -  Florid diabetic retinopathy floride.&#xD;
&#xD;
          -  Macular oedema due to causes other than diabetic retinopathy or in a context of&#xD;
             vitreomacular traction.&#xD;
&#xD;
          -  History of intravitreal treatment with anti-angiogenic agent or corticosteroids within&#xD;
             the 12 previous months.&#xD;
&#xD;
          -  History of treatment with laser in panretinal photocoagulation or focal laser on the&#xD;
             treated eye.&#xD;
&#xD;
          -  History of eye surgery or laser capsulotomy within the previous 6 months&#xD;
&#xD;
          -  History of renal failure requiring dialysis or kidney transplantation for diabetic&#xD;
             nephropathy.&#xD;
&#xD;
          -  Contra-indication for Tropicamide or Neo-synephrine&#xD;
&#xD;
          -  History of uncontrolled glaucoma or hypertonia&#xD;
&#xD;
          -  Patient with aphakia&#xD;
&#xD;
          -  Adult under guardianship&#xD;
&#xD;
          -  Pegnant or breast-feeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Catherine CREUZOT GARCHER, MD</last_name>
    <phone>3.80.29.51.73</phone>
    <phone_ext>+33</phone_ext>
    <email>catherine.creuzot-garcher@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine CREUZOT GARCHER, MD</last_name>
      <phone>3.80.29.51.73</phone>
      <phone_ext>+33</phone_ext>
      <email>catherine.creuzot-garcher@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>August 4, 2017</study_first_submitted>
  <study_first_submitted_qc>August 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 8, 2017</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

